Compass Pathways ($CMPS) Stock Hub: Q2 2026 Results, COMP360, Rolling NDA and the 2027 Launch Path

01 Executive Summary

Compass Pathways is one of the most advanced public companies attempting to turn a classic psychedelic into an FDA-regulated prescription treatment. Its lead program, COMP360, is a proprietary synthetic formulation of psilocybin being developed first for treatment-resistant depression, or TRD. The company’s investment narrative changed materially between early 2025 and July 2026: the clinical question is no longer built around one pivotal data event. Compass now has two positive Phase 3 trials, a rolling New Drug Application process already underway, an FDA Commissioner’s National Priority Voucher, a much stronger cash balance and a declared goal of being launch-ready by the end of 2026.

The latest company notice, dated July 29, sets the next near-term checkpoint: Compass will release Q2 and first-half 2026 results on August 5. The call matters less for quarterly earnings than for cash burn, launch-readiness spending, FDA interactions, manufacturing progress, the Q4 NDA target and the pace of the COMP202 PTSD program. No Q2 financial figures were available at this July 31 cut-off.^[17]

The latest material clinical update remains July 7, when Compass released 26-week results from Part B of COMP006. In a highly chronic TRD population, 39% of patients in the 25 mg arm achieved what the company defined as a clinically meaningful reduction in MADRS of at least 25% by week 6 and, on average, maintained that benefit through week 26. Separation between the 25 mg and 1 mg arms was reported as persisting through the blinded extension. The result strengthens the durability argument and complements the earlier COMP005 six-month data.^[1][2]

That headline is important, but it needs to be read correctly. The pivotal primary endpoint was the mean difference in change from baseline on the MADRS scale at week 6, not the post-hoc 25% reduction threshold. COMP006 met that primary endpoint with a 3.8-point difference between 25 mg and 1 mg and a p-value below 0.001. COMP005 had previously met its primary endpoint with a 3.6-point difference between 25 mg and placebo, also with a p-value below 0.001. The reproducibility across two large trials is the strongest part of the clinical package.^[13][20]

The six-month narrative is also more complex than “two doses lasted six months.” In COMP006, 58% of patients in the 25 mg arm received retreatment after week 9 under prespecified criteria, and antidepressant treatment was permitted during later portions of the study. Part B data after week 9 were presented as observed data. This does not erase the durability finding; it changes what the finding means. The emerging commercial profile is better understood as an intermittently administered treatment pathway with reassessment and possible retreatment, not necessarily a universal one- or two-dose cure.^[3]

The regulatory setup is unusually favorable on paper. COMP360 has FDA Breakthrough Therapy designation, the agency accepted a rolling NDA submission and Compass received a CNPV. The FDA describes the CNPV pilot as offering enhanced communication, rolling review and a target review period of one to two months for complete applications. The same FDA page explicitly states that normal safety, effectiveness and statutory approval standards still apply. There is no confirmed PDUFA date as of July 31, 2026, because the final NDA has not yet been completed and accepted as complete.^[6]

A July 16 peer-reviewed post-hoc analysis adds a smaller but commercially relevant piece of evidence. In 22 participants from the open-label Phase 2 PTSD study, administration-session transcripts showed silence for an average 78% of the session; support was described as minimal and non-directive rather than conventional psychotherapy. This may help Compass argue that the product is a drug administered with monitoring and support, not a psychotherapy bundle. It does not prove that commercial staffing will be inexpensive, and it is not pivotal TRD efficacy evidence.^[15][16]

The financial risk profile improved sharply across the first half of 2026. Cash and equivalents rose from $149.6 million at year-end 2025 to $466.0 million at March 31 and settled at $433.3 million at June 30. That improvement was financing-driven: Compass recorded $362.5 million of financing cash inflows during the quarter, including proceeds from an equity offering, ADS warrant exercises, pre-funded warrants and incremental debt. Shares outstanding increased from 96.1 million to 135.7 million, a rise of approximately 41.2% over six months. The result is a much stronger runway into the regulatory and launch window, but also a clear reminder that the company has financed development through material shareholder dilution.^[5]

For investors, the remaining thesis is a four-part execution problem. First, the final NDA package must hold up under an accelerated but still rigorous FDA review. Second, the company and regulators must establish a workable label, safety-monitoring framework and likely REMS. Third, federal and state controlled-substance scheduling must not delay access after approval. Fourth, treatment centers, trained professionals and payers must accept an administration model that is more operationally demanding than dispensing a daily pill.

The strongest part of the story

Compass has produced statistically significant primary-endpoint wins in two pivotal Phase 3 TRD trials and has now supplied company-reported six-month data from both programs. That combination materially reduces the pure clinical binary that defined CMPS in earlier years.

The part the market can still underestimate

Approval is not the same as adoption. A drug that requires controlled administration, hours of observation, trained personnel, certified sites, payer coordination and controlled-substance compliance can face a slow or uneven launch even with an acceptable label. The commercial system is part of the product.

02 What Changed Since the April 2026 Merlintrader Coverage

The earlier Merlintrader reports correctly identified April as the point when the psychedelic sector began moving from clinical speculation toward regulatory execution. Since those articles were published, several material facts have changed.

The most important editorial change is therefore not simply adding a new data paragraph. The entire frame of the Stock Hub must move from a pre-readout biotech model to a pre-approval and pre-commercial model. Clinical efficacy still matters, but manufacturing, site activation, payer coverage, provider training, REMS design, scheduling and launch productivity now deserve equal weight.

03 Company Overview: What Compass Pathways Is Building

Compass Pathways plc is a London-headquartered biotechnology company listed on the Nasdaq Global Select Market through American Depositary Shares under the ticker CMPS. Each ADS represents one ordinary share. The company is attempting to develop a regulated mental-health treatment platform around COMP360, a synthetic and proprietary psilocybin formulation administered with psychological support and monitoring in controlled clinical settings.

That description matters because Compass is not primarily trying to commercialize a conventional take-home pill, a consumer wellness product or a recreational psychedelic experience. Its model combines a pharmaceutical product with a treatment protocol, trained healthcare professionals, controlled administration, patient preparation, monitoring, follow-up and a network of third-party treatment sites. The operational pathway is likely to be shaped by the eventual FDA label and a risk-management program.

Compass retains global development and commercialization rights to COMP360. This gives the company greater upside if the product succeeds, but also leaves it responsible for the cost and difficulty of building the market. A partner can provide capital, infrastructure or validation; no such partner is required for the thesis to work, but full ownership means Compass must execute across regulatory, medical, manufacturing, reimbursement and commercial functions at the same time.

The business remains heavily concentrated. In its SEC filings, Compass states that COMP360 is its only therapeutic candidate in clinical development and that the company’s business substantially depends on successful approval and commercialization. PTSD broadens the indication strategy, but it is still the same core molecule and delivery system. This is not a diversified commercial pharmaceutical company. It is a late-stage, single-platform biotechnology company approaching its first possible launch.

Why CMPS matters beyond one ticker

Compass is a regulatory test case for the entire classic-psychedelic field. An acceptable NDA, workable label and credible launch pathway would provide read-through for other developers. A regulatory setback tied to trial design, safety, functional unblinding, manufacturing or treatment delivery could pressure the sector well beyond CMPS.

04 What COMP360 Actually Is — and What It Is Not

COMP360 is Compass Pathways’ investigational synthetic psilocybin formulation. Psilocybin is converted in the body to psilocin, which acts primarily through serotonin receptors, including 5-HT2A. The acute psychoactive experience is only one component of the proposed treatment effect. Compass is developing the drug inside a structured clinical framework designed to support safety, consistency and therapeutic implementation.

The company’s intended commercial proposition is based on rapid onset and durable benefit after intermittent treatment rather than daily administration. In theory, that could offer a different value proposition from chronic oral antidepressants and frequently administered interventions. In practice, the benefit must be large and durable enough to justify the resource burden of treatment sessions, supervision and follow-up.

It is therefore misleading to value COMP360 only as a molecule. The investable asset is better described as:

• The drug: a standardized synthetic 25 mg formulation, with lower-dose arms used in development.
• The evidence package: Phase 2 and two pivotal Phase 3 programs in TRD, plus growing long-term safety and durability data.
• The treatment model: preparation, administration, monitoring and post-session support.
• The regulatory framework: the label, controlled-substance rescheduling and any REMS requirements.
• The delivery network: qualified sites and trained professionals capable of treating patients at commercial scale.
• The reimbursement architecture: coverage for both the drug and the clinical services surrounding administration.

This creates a potential moat, because a competitor must reproduce more than chemical supply. It also creates friction, because every additional requirement can reduce site throughput, limit geographic access or increase total treatment cost.

Intellectual property

Compass says its patent portfolio and expected exclusivity extend beyond 2038. That claim should be understood as a company expectation, not an uncontested guarantee. Patents can be challenged, narrowed or designed around, and psilocybin itself is a known compound. The strategic value of the portfolio will depend on the enforceability of formulation, manufacturing, treatment and related claims, as well as regulatory exclusivity and the practical difficulty of reproducing the approved system.

05 Treatment-Resistant Depression: Large Need, Difficult Market

Treatment-resistant depression generally refers to major depressive disorder that has not responded adequately to at least two appropriate antidepressant treatments. Definitions differ across studies, payers and clinical practice, but the central issue is consistent: a substantial group of patients continues to experience severe symptoms after conventional options fail.

Compass cites an estimate of roughly four million U.S. patients living with TRD. Its Phase 3 population was not a mild or newly diagnosed group. In COMP006, the average current depressive episode had lasted more than three years and participants had experienced more than six lifetime depressive episodes on average. Baseline MADRS scores were around 32, and a majority of patients in each arm were categorized as having severe depression at baseline.^[3]

The opportunity is large, but headline prevalence is not the same as an immediately addressable commercial market. A real-world funnel would narrow through diagnosis, prior treatment documentation, contraindications, patient willingness, insurance authorization, geographic access, provider capacity and the ability to dedicate a full treatment day. The initial market may therefore be concentrated in specialized centers and among patients with severe disease who have exhausted conventional options.

The treatment landscape already includes oral antidepressant switches and combinations, augmentation with antipsychotic agents or other drugs, psychotherapy, transcranial magnetic stimulation, electroconvulsive therapy and intranasal esketamine. COMP360 does not need to replace all of these options to become commercially meaningful. It does need to establish a convincing place in the treatment sequence and demonstrate that its durability and patient outcomes justify the operational complexity.

For payers, the relevant economic question may not be the drug price alone. They will likely consider total cost of care: facility time, professional services, monitoring, repeat dosing, follow-up, adverse-event management and the possibility that a durable response reduces downstream healthcare utilization. A positive pharmacoeconomic case could support premium value. A fragmented reimbursement model could slow adoption even after approval.

06 The Phase 3 Program: COMP005 and COMP006

Compass designed two pivotal studies with different dosing and comparator structures. That is strategically useful because the trials address both reproducibility and the potential contribution of a second dose.

Why two positive pivotal trials matter

Psychiatric trials are difficult. Placebo response can be high, rating scales are variable and patient populations are heterogeneous. Psychedelic studies add another methodological challenge because the acute effects make treatment allocation difficult to conceal. Against that background, statistically significant wins in two large Phase 3 trials materially strengthen the evidence package.

The absolute placebo- or control-adjusted differences of 3.6 and 3.8 MADRS points are not enormous. The argument for clinical value rests on the full profile: rapid onset, consistency across trials, durability, intermittent administration and the severity of the population. The FDA will review far more than a headline effect size, including sensitivity analyses, missing data, site effects, concomitant treatments, safety, durability, protocol deviations and whether the totality of evidence supports a favorable benefit-risk balance.^[20][13]

The primary endpoint versus the “39%” headline

This distinction is essential. The primary endpoint in both trials was the difference between groups in change from baseline in total MADRS score at week 6. The 39% figure highlighted in July refers to a post-hoc threshold defined by Compass as at least a 25% reduction from baseline. It is not the same thing as a conventional 50% response definition, and it was not the pivotal primary endpoint.

That does not make the 39% figure meaningless. It helps illustrate the proportion of patients achieving a level of improvement that Compass considers clinically meaningful in a severe TRD population. It should simply be presented with its definition and analytical status, rather than converted into an unqualified “response rate.”

Blinding and comparator design

COMP005 used placebo. COMP006 used a low 1 mg dose as the main control for the 25 mg comparison, with a 10 mg arm also included. The low-dose comparator may help create some treatment expectancy or perceptual effects, but no psychedelic trial can fully eliminate the risk that participants and raters infer assignment. Functional unblinding remains a sector-wide issue and was one of the reasons investors became more demanding after earlier regulatory problems elsewhere in psychedelic drug development.

Compass has stated that its Phase 3 program reflects key principles in FDA psychedelic-drug guidance, but the company’s own risk factors acknowledge that the agency may disagree with study design, conduct or interpretation. The positive endpoints reduce risk; they do not remove regulatory discretion.

Phase 3 primary-endpoint reproducibility

Treatment difference versus the study comparator in change from baseline on MADRS at week 6. Larger absolute reductions favor COMP360; the trials used different control groups and should not be ranked as a head-to-head comparison.

Both primary endpoints were reported with p<0.001. Bars are normalized to a four-point scale for visual comparison; they do not show raw within-arm improvement or six-month durability.^[20][13]

07 July 7, 2026: What the COMP006 Six-Month Data Really Showed

The July update was the most important new information since the April Merlintrader articles. Compass reported rapid onset after both fixed doses, continued separation between the 25 mg and 1 mg arms through the blinded Part B period and an average maintenance of benefit through week 26 among the group meeting the company’s week-6 threshold.

The company’s presentation showed:

• 39% of participants in the 25 mg arm achieved at least a 25% reduction in MADRS at week 6.
• That group maintained benefit on average through week 26.
• 28% of patients who had achieved the ≥25% reduction but were not in remission at week 6 later entered remission following an additional dose in Part B.
• 58% of patients in the 25 mg arm received retreatment after week 9.
• Part B results after week 9 were based on observed data.

The correct durability interpretation

The data support a durable treatment strategy, but they do not prove that every responding patient can receive two doses and remain well for six months without additional intervention. Retreatment was built into the study, more than half of the 25 mg arm received it after week 9 and later antidepressant use was permitted. The likely real-world model is assessment-driven intermittent treatment, not a fixed universal dosing promise.

This nuance may ultimately help rather than hurt the commercial thesis. Depression is chronic and relapsing; a flexible retreatment framework may be more realistic than claiming permanent remission from one session. The commercial question will be whether the label allows clinicians enough flexibility to maintain benefit without creating a treatment burden that overwhelms patients, sites or payers.

Another limitation is disclosure maturity. The July material is company-reported top-line and presentation data. It is valuable and was filed through an 8-K, but it is not a substitute for a complete peer-reviewed publication or the FDA’s integrated review. Investors should watch for fuller analyses of remission, conventional response thresholds, time to relapse, retreatment distribution, concomitant medication, missing data and subgroup consistency.

Why the result still matters

Before July 7, the market knew that COMP006 had met its six-week primary endpoint. It did not yet know whether the apparent benefit would remain credible across the longer blinded extension. The new update reduces the risk that the second pivotal study would show rapid decay or a materially inconsistent pattern. Together with COMP005, it gives Compass a broader argument that COMP360 can deliver rapid improvement and support durability over six months within a retreatment-capable protocol.

08 Safety: Encouraging Aggregate Pattern, Serious Details Still Matter

Compass described COMP360 as generally well tolerated, with no new safety findings through 26 weeks. In COMP006, any treatment-emergent adverse event was reported in 94.6% of the 25 mg arm, 93.0% of the 10 mg arm and 86.7% of the 1 mg arm. High overall event rates are not surprising in a study involving an acutely psychoactive treatment and repeated observation, but they reinforce the need for controlled administration.

The most common events in the 25 mg arm included nausea, headache, anxiety, visual hallucination, fatigue, illusion or perceptual disturbance, dizziness, crying and increased blood pressure. Most events began on a dosing day, and the large majority of dosing-day events resolved within one day.^[3]

Serious treatment-emergent adverse events through week 26 were reported in 5.7% of the 25 mg arm, 3.5% of the 10 mg arm and 6.3% of the 1 mg arm. Compass emphasized that serious-event rates were similar between the 25 mg and 1 mg groups. The detailed table also included suicidal ideation in 1.4% of the 25 mg arm, 1.4% of the 10 mg arm and 2.8% of the 1 mg arm, as well as one suspected suicide in the 25 mg arm and one suicide attempt in the 1 mg arm. The public summary does not establish causality for individual events.

Safety cannot be reduced to “no new signal”

TRD is intrinsically associated with suicidality, and cross-arm rates require clinical context. Even so, every suicide-related event is material. The FDA will evaluate timing, causality, baseline risk, monitoring, protocol adherence and the broader database. A future label or REMS could include patient-selection, observation, provider-certification and emergency-management requirements.

The safety package is therefore neither obviously disqualifying nor trivial. The aggregate data appear compatible with continued regulatory review, but the operational burden of managing acute psychological and physiological effects will shape the commercial system. An approved treatment may need to be administered only in certified settings with trained personnel and post-dose observation. The eventual REMS, if required, could be one of the most important determinants of site throughput and adoption.

09 Regulatory Path: Breakthrough Therapy, Rolling NDA, CNPV and DEA Rescheduling

Breakthrough Therapy designation

The FDA granted Breakthrough Therapy designation to COMP360 for TRD in 2018. This designation is designed to facilitate interaction and potentially expedite development for drugs addressing serious conditions with preliminary evidence of substantial improvement. It is not an approval and does not guarantee a faster or positive review. Compass repeats that limitation in its SEC risk factors.

Rolling NDA submission

Following the Phase 3 readouts and FDA discussions, the agency accepted Compass’s request for a rolling NDA submission and review. Compass said on May 13 that sections had already been submitted, and on July 7 reaffirmed that rolling submission and initial review were underway. The final submission is targeted for Q4 2026.

Rolling review allows the FDA to begin evaluating completed sections before the entire application is submitted. It can improve issue identification and communication, but the application is not complete until the final modules are filed. Manufacturing, clinical, nonclinical, labeling and inspection readiness all remain relevant.

Commissioner’s National Priority Voucher

In April 2026, the FDA awarded COMP360 a Commissioner’s National Priority Voucher. The FDA says the CNPV pilot can provide enhanced communications, rolling review and a target one-to-two-month review timeline for a complete application. The agency also states that:

• the voucher is nontransferable;
• the same statutory and regulatory approval requirements apply;
• the scientific review remains with the relevant FDA center;
• the timeline can be extended for an incomplete application, manufacturing issues, ambiguous pivotal data, complexity or other reasons.

This is a meaningful regulatory advantage, especially when combined with the rolling submission. It is not a waiver of evidence standards. Because the pilot is new, execution risk exists on both sides: Compass must deliver a complete, inspection-ready application, and the FDA must implement an unusually compressed multidisciplinary review.

No PDUFA date yet

As of July 31, 2026, Compass has not announced a formal PDUFA action date. The company still needs to complete the NDA in Q4. The FDA must then determine whether the final application is sufficiently complete and establish the review framework. Any date circulated before an official company or FDA disclosure should be treated as an estimate, not a verified catalyst.

DEA and state scheduling

Psilocybin and psilocin remain controlled substances. Even after a favorable FDA decision, federal rescheduling is required before commercial launch, and state-level controlled-substance schedules may also need alignment. Compass explicitly conditions its first-half 2027 launch expectation on FDA approval and DEA rescheduling.

This creates a two-gate sequence: medical-product approval and controlled-substance implementation. A rapid FDA review would not automatically guarantee equally rapid nationwide access. Scheduling, site registration, storage, security, recordkeeping and state rules can create a staggered rollout.

Regulatory watchpoint

The decisive question is not whether the CNPV sounds fast. It is whether Compass can submit a complete package that lets the FDA use the fast pathway without pausing for major clinical, manufacturing, inspection or labeling issues.

10 Commercialization: The Treatment Network Is Part of the Product

Compass has said it intends to be launch-ready by the end of 2026. Preparations include key-opinion-leader and healthcare-provider education, payer engagement, site support, training and work related to federal and state scheduling. The company has recruited a commercial leadership team and has been studying delivery models with healthcare systems and specialty treatment networks.

The commercial opportunity could be substantial because severe TRD creates high medical and social costs. Yet this will not resemble a conventional primary-care antidepressant launch. A treatment session may require preparation, a controlled room, several hours of supervision, clinical staff, post-session monitoring, transportation planning and follow-up. Capacity depends on rooms, staff, scheduling and reimbursement—not only prescriptions written.

The main implementation questions

• Label: Which patients qualify, how many doses are permitted and when can retreatment occur?
• REMS: Must sites and providers be certified, and what monitoring is mandatory?
• Staffing: Which professionals can supervise administration, and how many are needed per patient?
• Throughput: How many patients can a site treat per room per week?
• Reimbursement: Are the drug, facility and professional services covered coherently?
• Patient logistics: Can patients travel, take time away from work and arrange post-treatment transport?
• Scheduling: How quickly can federal and state rules be aligned after FDA approval?
• Safety: Can sites handle acute anxiety, blood-pressure changes, psychological distress or emergency events?

Existing infrastructure from esketamine clinics, infusion centers, academic psychiatry programs and interventional-psychiatry practices could provide a starting point. However, an existing clinic is not automatically ready to deliver COMP360. Certification, room design, staffing ratios, controlled-substance handling and payer contracting may differ.

Commercial moat versus commercial bottleneck

The same complexity can be interpreted in opposite ways. A coordinated system can create barriers to entry and protect quality. It can also restrict access and slow revenue. The central operating metric after approval will not simply be the number of certified sites. Investors will need to know how many are activated, treating patients, obtaining reimbursement, achieving acceptable throughput and generating repeatable economics.

11 PTSD Expansion: A Valuable Second Indication, but Not Yet the Core Valuation Anchor

Compass is also developing COMP360 for post-traumatic stress disorder. An earlier open-label Phase 2 study enrolled 22 participants and met its primary safety endpoint, with the company reporting meaningful and sustained improvement in CAPS-5 and functional measures. The FDA accepted the company’s IND in January 2026, enabling a late-stage Phase 2b/3 trial called COMP202, also known as the Redefine Study.

COMP202 is designed as a multicenter, randomized, double-blind, controlled study with an open-label extension. Part A compares two 25 mg administrations with two 1 mg administrations, separated by roughly four weeks. The primary efficacy endpoint is change from baseline in CAPS-5 total severity score at week 8. The ClinicalTrials.gov record lists a planned enrollment of approximately 300 participants.^[9][10]

On July 16, Compass announced publication of a post-hoc analysis from the earlier 22-patient open-label PTSD study. Researchers measured speech during recorded sessions and reported that an average 78% of administration time was silent, versus approximately 25% to 30% in preparation and follow-up sessions. The authors concluded that Compass’s monitoring and support can be distinguished from conventional psychotherapy and from more directive psychedelic-assisted therapy models. The finding is exploratory, drawn from a small uncontrolled study and authored largely by Compass-affiliated researchers; its value is in clarifying the delivery model, not validating efficacy.^[15][16]

PTSD adds strategic option value for three reasons. First, the addressable population is large and treatment need remains high. Second, a positive program could expand the utilization of the same manufacturing and treatment infrastructure. Third, success in a second indication would reduce dependence on TRD alone.

It should not be overvalued prematurely. The program is earlier, the pivotal evidence is not yet available and PTSD trial design carries its own challenges. Near-term CMPS valuation remains dominated by the TRD NDA, approval process and commercial launch.

12 Financial Position: Stronger Runway, Still a Pre-Revenue Company

Compass ended the second quarter of 2026 with $433.3 million in cash and cash equivalents, against $149.6 million at December 31, 2025 and $466.0 million three months earlier. Management says that position funds operating expenses and capital expenditure into 2028, beyond the expected launch window. Debt rose to $50.7 million from $31.6 million at year-end. The improvement over December is real, but the sequential decline of roughly $33 million is the first clean look at what commercial preparation costs each quarter.

The financing trade-off through June: runway versus dilution

Cash and basic shares are charted in separate panels because they use different units. The visual shows the scale of the balance-sheet improvement and the shareholder cost incurred to obtain it.

Across the six months cash increased about 189.6% while shares outstanding increased about 41.2%, from 96,085,785 to 135,722,306. Additional paid-in capital rose from $783.6 million to $1,083.1 million, so roughly $299.5 million of the cash build came from issuing equity. The runway into 2028 was bought, not earned.^[5][17]

Why the reported net line is misleading, in both directions

Compass reported a net loss of $253.8 million for the second quarter, $1.88 per share. That is larger than the $162.6 million net loss reported for the entire first half. The arithmetic is not broken: the first quarter had produced net income of $91.2 million.

Both numbers are driven by the same non-cash line. Warrant liabilities are carried at fair value and move with the share price, so a rising share price produces an accounting loss and a falling one an accounting gain. In Q1 the fair-value change was a $130.9 million gain; in Q2 it was a $205.6 million charge. Across the half it nets to a $74.7 million charge, against a $16.9 million gain in the same period of 2025. The warrant liability itself now sits at $337.5 million, larger than the company’s entire shareholders equity.

The operating figures describe the business. Operating loss was $52.4 million in the quarter and $95.3 million across the half, against $42.9 million and $92.5 million a year earlier. Costs are rising because commercial preparation is rising, not because research is: R&D fell to $29.2 million from $30.3 million while G&A rose 84% to $23.2 million. For valuation the operating loss, the cash balance and the share count matter; the headline net line does not.

Runway assessment

A simple annualization of Q1 operating cash use would imply roughly $192 million per year and approximately 2.4 years of cash before considering debt, interest, changing launch costs, working capital, milestone payments or future revenue. That rough calculation is not a forecast. Commercial readiness can raise spending, while completion of major trials can reduce some R&D costs. Management’s formal guidance remains runway into 2028.

The balance sheet substantially reduces the probability that Compass must raise emergency capital before the NDA decision. It does not remove future financing risk. A slower launch, a required additional study, an expanded PTSD program or a decision to build more commercial infrastructure could consume capital rapidly.

13 Capital Structure and Dilution: The Balance Sheet Was Not Free

The financial transformation came with a major increase in share count. Basic ordinary shares outstanding rose from 96,085,785 at December 31, 2025 to 134,923,295 at March 31, 2026—approximately 40.4% growth in one quarter.

Q1 financing cash inflows totaled $362.5 million. They included:

• $140.6 million of net proceeds from ordinary shares and pre-funded warrants;
• $87.9 million from ADS warrant exercises;
• $115.3 million from pre-funded warrants associated with ADS warrant exercises;
• $18.6 million of net long-term debt proceeds;
• smaller option and pre-funded-warrant proceeds.

The company also has a February 2025 ATM agreement that permits up to $150 million of ADS sales. As of March 31, 2026, Compass said it had not sold ADSs under that newer facility. The ATM remains a financing option and therefore a potential source of future dilution.

Hercules debt

The amended Hercules facility provides for up to $150 million across multiple tranches, subject to conditions. A $50 million term loan was funded in January 2026, partly refinancing the prior balance. Borrowings bear the greater of 9.75% or the Wall Street Journal prime rate plus 2.75%. Payments are interest-only until the first principal payment due in the first quarter of 2029, subject to potential milestone-based deferral, with scheduled maturity in January 2031. Compass reported an effective interest rate of 12.9% at March 31, 2026.

Debt extends flexibility but adds covenants, interest expense and end-of-term charges. It also means that a cash-based enterprise-value calculation should not simply subtract the full $433 million without adding debt and considering warrant-related claims.

Basic versus fully diluted capitalization

The 135.7 million figure is the share count at June 30, 2026. Pre-funded warrants, ordinary warrants, options and restricted stock can increase the effective fully diluted count. Some warrant liabilities also revalue with the share price, creating non-cash volatility in reported earnings. Investors comparing market capitalization across periods should use consistent share-count assumptions.

Dilution conclusion

Compass used a favorable catalyst window to fund the company through its expected approval and launch period. That was strategically rational and materially reduced solvency risk. It also redistributed future value across a much larger share base. Both statements can be true at the same time.

14 Management, Governance and Ownership

Leadership

Kabir Nath, Chief Executive Officer, leads the company through the NDA and launch transition. His background includes senior pharmaceutical leadership at Otsuka, which is relevant as Compass moves from clinical development toward commercialization.

Dr. Guy Goodwin, Chief Medical Officer, is responsible for the clinical and medical strategy. The regulatory package will depend heavily on how the company presents efficacy, safety, retreatment and the practical treatment framework.

Teri Loxam, Chief Financial Officer, oversees capital allocation during a period when Compass must balance runway preservation with launch spending and expansion into PTSD.

The management challenge is changing. Running pivotal trials and raising capital are not the same as launching a controlled-substance psychiatric treatment. Success now depends on cross-functional execution: FDA interactions, manufacturing, inspection readiness, medical affairs, provider training, payer contracting, scheduling and site activation.

Institutional ownership snapshot

The 2026 proxy reported beneficial ownership as of April 6, 2026 using 134.9 million shares outstanding. RTW Investments and entities affiliated with Deep Track were each listed at 9.99%, with 9.47 million and 9.27 million shares respectively. The 9.99% figures may reflect beneficial-ownership limitations and should be treated as a dated filing snapshot rather than a current live position.^[11]

CEO Kabir Nath was listed as beneficially owning roughly 1.02 million shares and rights exercisable within the SEC calculation window. Other directors and officers held smaller positions. Insider ownership aligns management with shareholders to a degree, but institutional sponsorship does not remove clinical, regulatory or commercial risk.

Analyst coverage

Compass’s official investor-relations page lists coverage from B. Riley, BTIG, Canaccord Genuity, Cantor Fitzgerald, Cowen, Evercore ISI, H.C. Wainwright, Jefferies, Maxim, Morgan Stanley, LifeSci Capital, Oppenheimer, RBC Capital Markets, Stifel, Van Lanschot Kempen, Wells Fargo and Wolfe Research. The page identifies Benjamin J. Burnett as the Wells Fargo analyst, but it does not publish his rating or target.^[12]

The newest publicly reported change was Wells Fargo’s July 27 initiation at Equal Weight with a $13 price target. The reported argument separated regulatory probability from commercial value: two positive Phase 3 studies may support approval, while efficacy relative to Spravato and fast-following competition could constrain the ultimate opportunity. This is one analyst’s opinion reported by a secondary market-news source, not a company forecast or an independently verified valuation.^[18]

Other post-COMP006 targets reported by market-data services span a very wide range, illustrating how sensitive CMPS valuation is to assumptions about approval timing, patient throughput, pricing and peak penetration. Analyst targets can change quickly after data, financing and share-count changes and should never substitute for a model built from approved labeling, addressable patients, treatment capacity, reimbursement, competition and dilution.

15 Competition and the Broader Psychedelic Sector

Compass competes at three levels.

1. Existing TRD treatments

Current options include medication changes and combinations, augmentation strategies, psychotherapy, transcranial magnetic stimulation, electroconvulsive therapy and esketamine. These treatments have established clinicians, reimbursement pathways and real-world familiarity. COMP360 must offer enough benefit, durability or patient preference to earn a place in the sequence.

2. Other psychedelic and rapid-acting programs

Multiple companies and academic groups are developing psilocybin, DMT-related compounds, 5-MeO-DMT, LSD-derived treatments, MDMA-related approaches and other rapid-acting neuropsychiatric drugs. They differ in indication, session duration, intellectual property, trial design and the degree of psychological support. A shorter treatment session could have commercial advantages even if efficacy is similar. A more durable product could justify a longer session.

The competitive landscape changed materially on July 16 when Eli Lilly agreed to acquire AtaiBeckley for approximately $2.8 billion upfront plus up to $1.0 billion in milestone-linked consideration. Lilly gains BPL-003, an intranasal 5-MeO-DMT program in Phase 3 development for TRD that is designed around an in-clinic visit of roughly two hours. The transaction is external validation that large pharma sees strategic value in rapid-acting psychedelic-derived treatments. For Compass, it is also a warning: a future competitor may have Lilly’s development, payer and commercial infrastructure behind it.^[19]

3. Non-commercial or lower-cost psilocybin access

Compass’s filings acknowledge that nonprofit, academic or state-level models could eventually provide psilocybin-based services at lower cost or outside a conventional branded-drug framework. FDA approval, standardized manufacturing and reimbursed medical delivery would differentiate COMP360, but the presence of alternative access models could influence pricing and patient demand.

Sympathy-play dynamics

CMPS remains one of the sector’s most important regulatory leaders. Major Compass developments can move other psychedelic names even when those companies have different molecules, indications or timelines. That “sympathy” behavior is a trading phenomenon, not proof that a Compass result changes another company’s intrinsic probability of success. Each peer still requires its own clinical, financial and regulatory analysis.

For broader context, see Merlintrader’s sector analysis: FDA, Psychedelics and the New Hunt for Sympathy Plays.

16 Valuation Framework: From Binary Biotech to Launch-Execution Asset

At the August 5, 2026 close of $13.58, multiplying the price by the June 30 share count of 135.7 million produces an illustrative equity value of approximately $1.84 billion. Subtracting June 30 cash of $433.3 million and adding debt carrying value of $50.7 million produces an illustrative enterprise value near $1.46 billion. A live-data provider separately indicated a market capitalization near $1.51 billion, reflecting a different share-count basis. These are mixed-date estimates and exclude adjustments for warrant liabilities, fully diluted shares, future cash burn and other claims. They are useful only as a rough frame pending the August 5 financial update.

Traditional earnings multiples are not meaningful. Compass has no approved product revenue, and Q1 net income was driven by a non-cash warrant revaluation. A more appropriate valuation process is scenario-based.

Key model variables

• Probability and timing of FDA approval;
• DEA and state rescheduling speed;
• Final label and retreatment flexibility;
• REMS burden and treatment-session duration;
• Addressable TRD population after payer criteria;
• Drug price and reimbursement for surrounding services;
• Number of certified and active treatment sites;
• Patients treated per site per month;
• Persistence, retreatment frequency and real-world outcomes;
• Gross margin and commercial support cost;
• PTSD probability-adjusted value;
• Future dilution and debt use.

Why simple peak-sales estimates can mislead

A model that multiplies four million U.S. TRD patients by an assumed treatment price will dramatically overstate near-term opportunity. Commercial adoption is constrained by diagnosis, eligibility, payer authorization, provider capacity and patient logistics. Conversely, a model that treats COMP360 as just another antidepressant pill may understate the value of durable intermittent treatment and the possibility of premium reimbursement.

The most informative early launch metrics would be certified sites, activated sites, payer coverage, patient starts, average time from prescription to treatment, treatment-room utilization, reimbursement success and retreatment patterns. Until those data exist, valuation will remain highly sensitive to assumptions.

What the market is paying for now

The current enterprise-value frame reflects more than two positive trials. It also discounts a meaningful probability of approval and some commercial success. The remaining upside or downside will increasingly depend on how much of the theoretical TRD opportunity can pass through the real-world delivery bottleneck. The Wells Fargo initiation is useful as a counterweight to the most optimistic coverage: the core disagreement is no longer simply “will FDA approve?” but “how differentiated and scalable will COMP360 be if approved?”

17 Catalyst Map and Timeline

COMP005 met the Phase 3 primary endpoint

A single 25 mg dose produced a 3.6-point placebo-adjusted difference in MADRS change at week 6, with p<0.001.^[20]

FDA accepted PTSD IND

The acceptance enabled initiation of the COMP202 Phase 2b/3 PTSD program.

COMP006 met the second Phase 3 primary endpoint

Two fixed 25 mg doses beat the 1 mg control by 3.8 MADRS points at week 6, with p<0.001.

Rolling review and CNPV acceleration

The FDA granted rolling submission and review and awarded a Commissioner’s National Priority Voucher.

Q1 results confirmed $466 million cash

Compass disclosed a financing-strengthened balance sheet and runway into 2028.

COMP006 26-week Part B data

The company reported sustained separation and average maintenance of benefit through six months, with retreatment playing a substantial role.

Peer-reviewed monitoring and support analysis

The PTSD study analysis reported that administration sessions were silent for an average 78% of the time, supporting Compass’s distinction between monitoring/support and conventional psychotherapy.

Wells Fargo initiated at Equal Weight

The reported $13 target and cautious commercial framing highlighted the growing split between approval confidence and peak-sales confidence.^[18]

August results date confirmed

Compass scheduled its Q2 and first-half 2026 release and call for August 5.

Q2 and first-half 2026 results

The immediate investor checks are cash burn, post-financing capitalization, NDA timing, launch-readiness costs, manufacturing progress and COMP202 execution.

Complete the rolling NDA submission

This remains the principal regulatory catalyst. A formal review clock or PDUFA date has not yet been announced.

FDA CNPV review

The pilot targets a one-to-two-month review but allows extensions. Approval is not guaranteed.

DEA and state rescheduling

Commercial launch depends on controlled-substance implementation as well as medical-product approval.

Potential U.S. launch

Subject to approval, rescheduling, site readiness and payer access.

Secondary future updates to monitor

• August 5 cash, operating burn, share count, launch spending and management guidance;
• Fuller COMP006 analyses, publications and 52-week Part C data;
• FDA communications on application completeness, labeling, advisory-committee needs or review timing;
• Manufacturing and inspection readiness;
• Details of any REMS and provider/site certification;
• COMP202 enrollment and PTSD program milestones;
• Updated cash burn as launch investment rises;
• ATM use, warrant exercises or additional financing;
• Payer and treatment-site readiness metrics.

18 Scenario Analysis

Bull scenario

The final NDA is complete and review proceeds close to the CNPV target. The FDA accepts the efficacy and safety package without requiring another pivotal study. Label and REMS permit practical retreatment, DEA rescheduling follows promptly and enough states align for a meaningful 2027 launch. Payers recognize the value of durable intermittent treatment, existing interventional-psychiatry infrastructure activates quickly and early site productivity supports a credible path to significant revenue. PTSD adds a second high-value growth option.

Base scenario

COMP360 is approvable, but review takes longer than the headline one-to-two-month target and the label includes meaningful safeguards. Federal approval is followed by uneven scheduling and payer adoption. Launch begins in 2027 but ramps gradually because site certification, staffing, patient logistics and reimbursement require time. Compass has sufficient cash to execute, yet burn remains high and the market debates the long-term margin of a service-intensive treatment model.

Bear scenario

The FDA identifies material issues in efficacy interpretation, durability, suicidality, functional unblinding, manufacturing or treatment delivery. Review is extended, an advisory committee is difficult, or another study is required. Alternatively, approval occurs but the REMS, scheduling and reimbursement framework makes access too restrictive. Commercial uptake disappoints, cash burn accelerates and Compass returns to the capital markets before the revenue base is established.

19 Red Flags and the Monitoring Checklist

Questions every quarterly update should answer

1. Is final NDA completion still on track for Q4 2026?
2. Have FDA interactions identified any new clinical, manufacturing or labeling work?
3. Is the CNPV timeline still achievable after the application is complete?
4. What will the retreatment framework look like?
5. How many treatment sites are identified, certified, activated and payer-ready?
6. How much cash is being consumed by launch preparation?
7. Has Compass used the ATM or issued additional equity-linked securities?
8. Is COMP202 enrolling on schedule?
9. Are state scheduling and reimbursement progressing in parallel with the FDA review?

20 Bottom Line

Compass Pathways enters the second half of 2026 in the strongest strategic position of its public-company history. Two Phase 3 trials met their primary endpoints. Six-month data from both programs support a durability narrative. The FDA has allowed a rolling NDA and awarded a CNPV. The balance sheet was funded into the expected launch window as of Q1, and the July 16 publication adds evidence that Compass’s administration model is monitoring-led rather than conventional psychotherapy.

Those achievements are real and materially de-risk the clinical story. They do not make CMPS a simple approval trade. The remaining risks are concentrated in the parts that often receive less attention before launch: the FDA’s full-data interpretation, safety and labeling, manufacturing readiness, REMS design, DEA and state scheduling, payer coverage, site capacity and the economics of a supervised treatment session.

The July 7 data sharpen the likely product profile. COMP360 may offer rapid and durable benefit to a subset of patients with severe TRD, but retreatment is an important component of the program. That could support a clinically realistic maintenance pathway while also increasing delivery complexity. The commercial winner will not merely be the company with a positive psychedelic trial. It will be the company that turns a tightly controlled treatment into a repeatable, reimbursed and scalable healthcare service.

For CMPS, the next immediate checkpoint is August 5: investors need confirmation that cash, burn, manufacturing and launch preparation remain aligned with the Q4 filing plan. The next decisive regulatory step is the complete Q4 2026 NDA. After that, the market will need to distinguish three events that are often blurred together: FDA approval, controlled-substance rescheduling and real commercial access. The company has cleared much of the clinical mountain. The final climb is regulatory, competitive and operational.

21 Frequently Asked Questions

No. COMP360 remains investigational. Compass is submitting a rolling NDA and expects to complete the application in Q4 2026.

No confirmed PDUFA date had been announced as of July 31, 2026. The FDA must first receive and evaluate the complete NDA and establish the review framework.

The next confirmed event is Q2 and first-half 2026 results on August 5 at 8:00 a.m. ET. The principal regulatory catalyst remains completion of the rolling NDA submission in Q4 2026. FDA review timing, labeling, any advisory-committee decision and DEA rescheduling would follow.

In a post-hoc analysis of 22 participants from Compass’s open-label Phase 2 PTSD study, an average 78% of administration-session time was silent. The authors characterized the support as minimal and non-directive, distinct from conventional psychotherapy. The analysis helps define the delivery model but is not pivotal TRD efficacy evidence and does not remove commercial supervision costs.

Compass reported that 39% of 25 mg patients achieved at least a 25% MADRS reduction at week 6 and maintained average benefit through week 26. Separation from the 1 mg arm persisted through the blinded extension. Retreatment was substantial: 58% of the 25 mg arm received another dose after week 9.

No. The pivotal primary endpoint was the week-6 between-group difference in change from baseline in MADRS. The 39% threshold analysis was presented post hoc and used a ≥25% reduction definition.

Psilocybin and psilocin are controlled substances. Even if the FDA approves COMP360 as a medical product, federal scheduling must be changed before commercial launch, and state rules may also need to align.

Compass reported $433.3 million of cash and equivalents at June 30, 2026, with company runway guidance into 2028. Additional paid-in capital rose from $783.6 million to $1,083.1 million across the half, so most of the build came from issuing equity. The Q1 cash increase was largely produced by equity, warrant and debt financing.

No in an operating sense, and the second quarter shows it from the opposite side. In Q1 the company reported $91.2 million of net income because of a $130.9 million non-cash gain on warrant liabilities; in Q2 it reported a $253.8 million net loss because the same line swung to a $205.6 million charge. Operating loss was $42.9 million in Q1 and $52.4 million in Q2.

Shares outstanding increased from 96.1 million to 135.7 million between year-end 2025 and June 30, 2026, roughly 41%. The company also has warrants, pre-funded warrants, options and an available ATM facility, and filed an automatic shelf registration on August 5, 2026.

COMP202, or the Redefine Study, is Compass’s Phase 2b/3 PTSD trial of COMP360. The FDA accepted the IND in January 2026, and the registered study is designed to compare two 25 mg administrations with two 1 mg administrations.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

22 Sources and Verification Trail

1. Compass Pathways — Six-month COMP006 Phase 3 data, July 7, 2026.
2. Compass Pathways Form 8-K, filed July 7, 2026.
3. Compass Pathways — COMP006 data webcast presentation, July 7, 2026.
4. Compass Pathways — Q1 2026 financial results and business highlights, May 13, 2026.
5. Compass Pathways Form 10-Q for the quarter ended March 31, 2026.
6. U.S. FDA — Commissioner’s National Priority Voucher pilot program.
7. ClinicalTrials.gov — COMP005, NCT05624268.
8. ClinicalTrials.gov — COMP006, NCT05711940.
9. ClinicalTrials.gov — COMP202 / Redefine PTSD study, NCT07570654.
10. Compass Pathways — FDA acceptance of PTSD IND, January 7, 2026.
11. Compass Pathways 2026 proxy statement — ownership, management and governance.
12. Compass Pathways official analyst coverage list.
13. Compass Pathways — COMP006 week-6 primary endpoint, February 17, 2026.
14. SEC exhibit — amended Hercules loan and security agreement, January 5, 2026.
15. Compass Pathways — publication of PTSD monitoring and support analysis, July 16, 2026.
16. Journal of Psychopharmacology — “Silence is golden,” first published online July 16, 2026.
17. Compass Pathways — Q2 and first-half 2026 results scheduled for August 5, announced July 29, 2026.
18. The Fly via TipRanks — Wells Fargo initiated CMPS at Equal Weight with a reported $13 target, July 27, 2026. Secondary-source analyst report; target and rationale are opinions.
19. Eli Lilly — definitive agreement to acquire AtaiBeckley, July 16, 2026.
20. Compass Pathways — COMP005 week-6 primary endpoint, June 23, 2025.

Verification note: the latest Compass investor-relations item identified at the July 31 cut-off was the July 29 announcement of the August 5 results date. The latest material clinical update remains the July 7 COMP006 six-month release and related Form 8-K; the July 16 peer-reviewed paper concerns a post-hoc analysis of the smaller open-label PTSD study. Clinical results are company-reported unless otherwise stated and remain subject to full regulatory review.